Measurable residual disease in chronic lymphocytic leukemia

Measurable residual disease in chronic lymphocytic leukemia

Measurable residual disease (MRD) is defined as the presence of residual cancer cells after treatment in patients with clinically undetectable disease, who would otherwise be considered in complete remission. It is a highly sensitive parameter which indicates the disease burden and predicts survival...

Full description

Bibliographic Details
Main Authors: Giulia Benintende, Federico Pozzo, Idanna Innocenti, Francesco Autore, Alberto Fresa, Giovanni D’Arena, Valter Gattei, Luca Laurenti
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Oncology
Subjects:
measurable residual disease
chronic lymphocytic leukemia
flow cytometry
ASO-PCR
next generation sequencing
surrogate endpoint
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1112616/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1112616/full

Similar Items